Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | EYA2 | O00167 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
| ▸ | CTSD | P07339 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HMGCR | P04035 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21570100 | 0.86 | MVD (0.36) | HDAC6HDAC1HDAC2CTSLCTSB | |
| SCHEMBL393708 | 0.81 | TDP1 (0.32) | TDP1EYA2APPACEADRA1A | |
| SCHEMBL646025 | 0.80 | CA14 (0.38) | HDAC6HDAC1HDAC2CA14TDP1 | |
| SCHEMBL7342839 | 0.80 | HDAC6 (0.35) | HDAC6HDAC1HDAC2 | |
| SCHEMBL12928688 | 0.78 | HDAC6 (0.38) | HDAC6HDAC1HDAC2CA14DGAT1 | |
| SCHEMBL7719558 | 0.78 | HDAC6 (0.38) | HDAC6HDAC1HDAC2CA14TDP1 | |
| SCHEMBL78691 | 0.78 | CA14 (0.41) | HDAC6HDAC1HDAC2CA14TDP1 | |
| SCHEMBL2052653 | 0.77 | CA12 (0.41) | HDAC6HDAC1HDAC2GAALMNA | |
| SCHEMBL3913731 | 0.77 | HDAC6 (0.33) | HDAC6HDAC1HDAC2 | |
| SCHEMBL336495 | 0.77 | HDAC6 (0.37) | HDAC6HDAC1HDAC2CA14TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 265 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-02-12 | — | — | US | disclosed |
| US-12472165-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-11-18 | — | — | US | disclosed |
| US-20250332148-A1 | RILUZOLE PRODRUGS AND THEIR USE | BIOHAVEN THERAPEUTICS LTD (US) | 2025-10-30 | — | — | US | disclosed |
| US-12295942-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-05-13 | — | — | US | disclosed |
| US-12213965-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-02-04 | — | — | US | disclosed |
| US-12005047-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (US) | 2024-06-11 | — | — | US | disclosed |
| US-12005046-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (US) | 2024-06-11 | — | — | US | disclosed |
| US-20240091205-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2024-03-21 | — | — | US | disclosed |
| US-20240082417-A1 | PROTEIN-POLYMER DRUG CONJUGATES | ASANA BIOSCIENCES, LLC | 2024-03-14 | — | — | US | disclosed |
| US-6239125-B1 | ANTIVIRAL AGENTS AGAINST HERPES VIRUSES. | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2001-05-29 | — | — | US | disclosed |
| US-6194143-B1 | MEASUREMENT ACTIVITY BY MONITORING SUBSTRATE CLEAVAGE | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2001-02-27 | — | — | US | disclosed |
| EP-1021404-A1 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF HCMV INFECTIONS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2000-07-26 | — | — | EP | disclosed |
| US-6030972-A | 2- OR 5-AMINOMETHYL,2- OR 5-CYANOPYRIMIDINES AS INTERMEDIATES OF ANTICOAGULANTS IN EXTRACORPOREAL CIRCULATION (HEART-LUNG MACHINE, HEMODIALYSIS) | BASF AKTIENGESELLSCHAFT (DE) | 2000-02-29 | — | — | US | disclosed |
| WO-1999018071-A1 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF HCMV INFECTIONS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 1999-04-15 | — | — | WO | disclosed |
| EP-0873356-A1 | NOVEL DIPEPTIDE AMIDINES AS THROMBIN INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 1998-10-28 | — | — | EP | disclosed |
| US-5646121-A | CYTOMEGALOVIRUSES | BAYER AKTIENGESELLSCHAFT (DE) | 1997-07-08 | — | — | US | disclosed |
| WO-1996025426-A1 | NOVEL DIPEPTIDE AMIDINES AS THROMBIN INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 1996-08-22 | — | — | WO | disclosed |
| EP-0646597-A1 | New pseudopeptides with antiviral activity containing valine | BAYER AG (DE) | 1995-04-05 | — | — | EP | disclosed |
| EP-0443573-A2 | HIV protease inhibitors containing derived amino acids | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1991-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | IL6ST, GFRA3, GFRA1 | HDAC6 562/4885HDAC1 325/4885HDAC2 715/4885 |
| US-12005046-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | HDAC6 477/4885HDAC1 145/4885HDAC2 536/4885 |
| US-12005047-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | HDAC6 477/4885HDAC1 145/4885HDAC2 536/4885 |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | GFRA3, IL6ST, GFRA1 | HDAC6 566/4885HDAC1 328/4885HDAC2 747/4885 |
| US-12472165-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | HDAC6 477/4885HDAC1 145/4885HDAC2 536/4885 |
| US-12295942-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | HDAC6 477/4885HDAC1 145/4885HDAC2 536/4885 |
| US-20240091205-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | APEH, UGT1A9, ALDH3A1 | HDAC6 582/4885HDAC1 265/4885HDAC2 731/4885 |
| US-20250332148-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | HDAC6 477/4885HDAC1 145/4885HDAC2 536/4885 |
| US-12213965-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | HDAC6 477/4885HDAC1 145/4885HDAC2 536/4885 |
| US-20240082417-A1 | PROTEIN-POLYMER DRUG CONJUGATES | PBRM1, STAMBP, TSPO | HDAC6 846/4885HDAC1 1398/4885HDAC2 2735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.